Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development

Free Radical Biology and Medicine

Volumn 37, Issue 9, 2004, Pages 1304-1316

  Aviram, Michael ^a,b   Rosenblat, Mira ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Atherosclerosis; Cholesterol; Foam cell; Free radicals; HDL; LDL; Lipid peroxides; Lipoproteins; Macrophage; Paraoxonases 1, 2, 3 (PON 1, 2, 3)

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PARAOXONASE 2; PARAOXONASE 3; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; BIOACCUMULATION; CELL LEVEL; CELL PROTECTION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CYTOPATHOLOGY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FOAM CELL; GENETIC ASSOCIATION; HUMAN; HUMORAL IMMUNITY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; REVIEW; TRANSGENIC MOUSE;

ANIMALS; ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL; ESTERASES; FOAM CELLS; HUMANS; MODELS, CARDIOVASCULAR; OXIDATIVE STRESS;

MUS MUSCULUS;

EID: 5344238178     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2004.06.030     Document Type: Review

References (104)

1. R.A. Hegele Paraoxonase genes and disease Ann. Med. 31 1999 217 224
2. S.L. Primo-Parmo, R.C. Sorenson, J. Teiber, and B.N. La Du The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family Genomics 33 1996 498 507
3. R.C. Sorenson, C.L. Bisgaier, M. Aviram, C. Xsu, S. Billecke, and B.N. La Du Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity Arterioscler. Thromb. Vasc. Biol. 19 1999 2214 2225
4. M. Harel, A. Aharoni, L. Gaidukov, B. Brumshtein, O. Khersonsky, R. Meged, H. Dvir, R.B.G. Ravelli, A. McCarthy, L. Toker, I. Silman, J.L. Sussman, and D.S. Tawfik Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes Nat. Struct. Mol. Biol. 11 2004 412 419
5. S.T. Reddy, D.J. Wadleigh, V. Grijalva, C. Ng, S. Hama, A. Gangopadhyay, D.M. Shih, A.J. Lusis, M. Navab, and A.M. Fogelman Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids Arterioscler. Thromb. Vasc. Biol. 21 2001 542 547
6. C.J. Ng, D.J. Wadleigh, A. Gangopadhyay, S. Hama, V.R. Grijalva, M. Navab, A.M. Fogelman, and S.T. Reddy Paraoxonase-2 is an ubiquitously expressed protein with antioxidant properties, and is capable of preventing cell-mediated oxidative modification of low-density lipoprotein J. Biol. Chem. 276 2001 44444 44449
7. D.I. Draganov, and B.N. La Du Pharmacogenetics of paraoxonases: a brief review Naunyn-Schiedeberg's Arch. Pharmacol. 369 2004 78 88
8. H.-L. Li, D.-P. Liu, and C.-C. Liang Paraoxonase gene polymorphisms, oxidative stress, and diseases J. Mol. Med. 81 2003 766 779
9. I. Leviev, and R.W. James Promoter polymorphism of human paraoxonase gene and serum paraoxonase activities and concentrations Arterioscler. Thromb. Vasc. Biol. 20 2000 516 521
10. H. Mochizuki, S.W. Scherer, T. Xi, D.C. Nickle, M. Majer, J.J. Huizenga, L.C. Tsui, and M. Prochazka Human PON2 gene at 7q21.3: cloning, multiple mRNA, and missense polymorphism in coding seguence Gene 213 1998 149 157
11. B.N. La Du, M. Aviram, S. Billecke, M. Navab, S. Primo-Pharmo, R.C. Sorenson, and T.J. Standiford On the physiological role(s) of the paraoxonases Chem. Biol. Interact. 119-120 1999 379 388
12. B. Mackness, P.N. Durrington, and M.I. Mackness The paraoxonase gene family and coronary heart disease Curr. Opin. Lipidol. 13 2002 357 362
13. M. Aviram Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol. Med. 5 1999 381 386
14. P.N. Durrington, B. Mackness, and M.I. Mackness Paraoxonase and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 21 2001 473 480
15. B. Mackness, G.K. Davies, W. Turkie, E. Lee, D.H. Roberts, E. Hill, C. Roberts, P.N. Durrington, and M.I. Mackness Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler. Thromb. Vasc. Biol. 21 2001 1451 1457
16. B. Mackness, P.N. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study Circulation 107 2003 2775 2779
17. M. Rosenblat, T. Hayek, K. Hussein, and M. Aviram Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy Arterioscler. Thromb. Vasc. Biol. 24 2004 175 180
18. M.I. Mackness, D. Harty, D. Bhatanagar, P.H. Wincocour, S. Arrol, M. Ishola, and P.N. Durrington Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus Atherosclerosis 86 1991 193 197
19. C.A. Abbott, M.I. Mackness, S. Kumar, A.J. Boulton, and P.N. Durrington Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins Arterioscler. Thromb. Vasc. Biol. 15 1995 1812 1818
20. M. Boemi, I. Leviev, C. Sirolla, C. Pieri, M. Marra, and R.W. James Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives: influence on the ability of HDL to protect LDL from oxidation Atherosclerosis 155 2001 229 235
21. C. Letellier, M.R. Durou, A.M. Jouanolle, J.Y. Le Gall, J.Y. Poirier, and A. Ruelland Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications Diabetes Metab. 28 2002 297 304
22. M. Aviram, M. Rosenblat, C.L. Bisgaier, R.S. Newton, S.L. Primo-Parmo, and B.N. La Du Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase J. Clin. Invest. 101 1998 1581 1590
23. M.I. Mackness, H. Boullier, M. Hennuyer, B. Mackness, M. Hall, A. Tailleux, P. Duriez, B. Delfly, P.N. Durrington, J.C. Fruchart, N. Duverager, J.M. Cailloud, G. Castro, and A. Bouiller Paraoxonase activity is reduced by a pro-atherogenic diet in rabbits Biochem. Biophys. Res. Commun. 269 2000 232 236
24. M.C. Garin, R.W. James, P. Dussoix, H. Blanche, P. Passa, P. Froguel, and J. Ruiz Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes J. Clin. Invest. 99 1997 62 66
25. Y. Imai, H. Morita, H. Kurihara, T. Sugiyama, N. Kato, A. Ebihara, C. Hamada, Y. Kurihara, T. Shindo, Y. Oh-hashi, and Y. Yazaki Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases Atherosclerosis 149 2000 435 442
26. N. Watzinger, H. Schmidt, M. Schumacher, R. Schmidt, B. Eber, F.M. Fruhwald, R. Zweiker, G.M. Kostner, and W. Klein Human paraoxonase 1 gene polymorphisms and the risk of coronary heart disease: a community based study Cardiology 98 2002 116 122
27. T. Ito, H. Yasue, M. Yoshimura, S. Nakamura, M. Nakayama, Y. Shimasaki, E. Harada, Y. Mizuno, H. Kawano, and H. Ogawa Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm Hum. Genet. 110 2002 89 94
28. Q. Chen, S.E. Rels, C.M. Kammerer, D.M. McNamara, R. Holubkov, B.L. Sharaf, G. Sopko, D.F. Pauly, C.N. Merz, and M.I. Kamboh Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study Am. J. Hum. Genet. 72 2003 13 22
29. X. Wang, Z. Fan, J. Huang, S. Su, Q. Yu, J. Zhao, R. Hui, Z. Yao, Y. Shen, B. Qiang, and D. Gu Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population Arterioscler. Thromb. Vasc. Biol. 23 2003 328 334
30. G. Fortunate, P. Rubba, S. Panico, D. Tronto, N. Tinto, C. Mazzaccara, M. De Michele, A. Iannuzzi, D.F. Vitale, F. Salvatore, and L. Sacchetti A paraoxonase gene polymorphism, PON1 (55), as an independent risk factor for increased carotid intima-media thickness in middle-aged women Atherosclerosis 167 2003 141 148
31. I. Leviev, O. Poirier, V. Nicaud, A. Evans, F. Kee, D. Arveiler, C. Morrisson, F. Cambien, and R.W. James High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients Atherosclerosis 16 2002 463 467
32. G.P. Jarvik, T.S. Hatsukami, C. Carlson, R.J. Richter, R. Jampsa, V.H. Brophy, S. Margolin, M. Rieder, D. Nickerson, G.D. Schellenberg, P.J. Heagerty, and C.E. Furlong Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease Arterioscler. Thromb. Vasc. Biol. 23 2003 1465 1471
33. D.M. Shih, L. Gu, Y.R. Xia, M. Navab, W.F. Li, S. Hama, L.W. Catelliani, C.E. Furlong, L.G. Costa, A.M. Fogelman, and A.J. Lusis Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis Nature 394 1998 284 287
34. D.M. Shih, Y.R. Xia, E. Miller, L.W. Castellani, G. Subbanagounder, H. Cheroutre, K.F. Faull, J.A. Berliner, J.L. Witztum, and A.J. Lusis Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis J. Biol. Chem. 275 2000 17527 17535
35. A. Tward, Y.R. Xia, X.P. Wang, Y.S. Shi, C. Park, L.W. Castellani, A.J. Lusis, and D.M. Shih Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice Circulation 106 2002 484 490
36. F.R. Leus, M. Zwart, J.J. Kastelein, and H.A. Voorbij PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients Atherosclerosis 154 2001 641 649
37. J.P. Pan, S.T. Lai, S.C. Chiang, S.C. Chou, and A.N. Chiang The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser311 polymorphism of human paraoxonase (PON)-2 gene Zhonghua Yi Xue Za Zhi (Taipei) 65 2002 415 421
38. M. Navab, J.A. Berliner, A.D. Watson, S.Y. Hama, M.C. Territo, A.J. Lusis, D.M. Shih, B.J. Van Lenten, J.S. Frank, L.L. Demer, P.A. Edwards, and A.M. Fogelman The yin and yang of oxidation in the development of the fatty streak: a review based on the 1004 George Lyman Duff Memorial Lecture Arterioscler. Thromb. Vasc. Biol. 16 1996 831 842
39. M.I. Mackness, S. Arrol, and P.N. Durrington Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein FEBS Lett. 286 1991 152 154
40. M.I. Mackness, S. Arrol, C.A. Abbott, and P.N. Durrington Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis 104 1993 129 135
41. M.I. Mackness, P.N. Durrington, and B. Mackness How high-density lipoprotein protects against the effects of lipid peroxidation Curr. Opin. Lipidol. 11 2000 383 388
42. Z. Ahmed, A. Ravandi, G.F. Maguire, A. Emili, D.I. Draganov, B.N. La Du, A. Kuksis, and P.W. Connelly Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (pon-1) during high density lipoprotein oxidation with a peroxynitrite donor J. Biol. Chem. 276 2001 24473 24481
43. P. Sanvanich, B. Mackness, S.J. Gaskell, P. Durrington, and M. Mackness The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein Biochem. Biophys. Res. Commun. 300 2003 501 506
44. M. Aviram, S. Billecke, R. Sorenson, C. Bisgaier, R.S. Newton, M. Rosenblat, J. Erogul, C. Hsu, C. Dunlp, and B.N. La Du Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R Arterioscler. Thromb. Vasc. Biol. 18 1998 1617 1624
45. J.F. Teiber, D.I. Draganov, and B.N. La Du Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3 Biochem. Pharmacol. 66 2003 887 896
46. R. Malin, S. Laine, V. Rantalaiho, O. Wirta, A. Pasternack, H. Jokela, H. Alho, T. Koivula, and T. Lehtimaki Lipid peroxidation is increased in paraoxonase L55 homozygotes compared with M-allele carriers Free Radic. Res. 34 2001 477 484
47. A. Mertens, P. Verhamme, J.K. Bielicji, M.C. Phillips, R. Quarck, W. Verreth, D. Stengel, E. Ninio, M. Navab, B. Mackness, M. Mackness, and P. Holvoet Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis Circulation 107 2003 1640 1646
48. T. Hayek, E. Pavlotzky, S. Hamoud, R. Coelman, S. Keidar, M. Aviram, and M. Kaplan Tissue angiotensin-converting enzyme (ACE) deficiency leads to a reduction in oxidative stress and in atherosclerosis: studies in ACE-knockout mice type 2 Arterioscler. Thromb. Vasc. Biol. 23 2003 2090 2096
49. M.N. Oda, J.K. Bielicki, T.T. Ho, T. Berger, E.M. Rubin, and T.M. Forte Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins Biochem. Biophys. Res. Commun. 290 2002 921 927
50. M. Aviram, M. Rosenblat, S. Billecke, J. Erogul, R. Sorenson, C.L. Bisgaier, R.S. Newton, and B.N. La Du Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants Free Radic. Biol. Med. 26 1999 892 904
51. L. Jaouad, C. Milochevitch, and A. Khalil PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity Free Radic. Res. 37 2003 77 83
52. S.D. Nguyen, and D.E. Sok Beneficial effect of oleolytated lipids on paraoxonase 1: protection against oxidative inactivation and stabilization Biochem. J. 375 2003 275 285
53. M. Aviram, L. Dorenfeld, M. Rosenblat, N. Volkova, M. Kaplan, R. Coelman, T. Hayek, D. Presser, and B. Fuhrman Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL and platelet aggregation; studies in humans and in the atherosclerotic apolipoprotein E deficient mice Am. J. Clin. Nutr. 71 2000 1062 1076
54. M. Kaplan, T. Hayek, A. Raz, R. Coleman, L. Dorenfeld, J. Vaya, and M. Aviram Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis J. Nutr. 131 2001 2082 2089
55. T. Hayek, B. Fuhrman, J. Vaya, M. Rosenblat, P. Belinky, R. Coelman, A. Elis, and M. Aviram Reduced progression of atherosclerosis in apolipoprotein E deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation Arterioscler. Thromb. Vasc. Biol. 17 1997 2744 2752
56. B. Fuhrman, and M. Aviram Preservation of paraoxonase activity by wine flavonoids: possible role in protection of LDL from lipid peroxidation Ann. N.Y. Acad. Sci. 957 2002 321 324
57. M. Aviram, M. Rosenblat, D. Gaitini, S. Nitecki, A. Hoffman, L. Dorenfeld, N. Volkova, D. Presser, J. Attias, H. Liker, and T. Hayek Pomegranate juice consumption for 3 years by patients with carotid artery stenosis (CAS) reduces common carotid intima-media thickness (IMT), blood pressure and LDL oxidation Clin. Nutr. 23 2004 423 433
58. M. Aviram, M. Rosenblat, C.L. Bisgaier, and R.S. Newton Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation Atherosclerosis 138 1998 271 280
59. B. Fuhrman, L. Koren, N. Volkova, T. Hayek, and M. Aviram Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes Atherosclerosis 164 2002 179 185
60. M. Tomas, M. Senti, F. Garcia-Faria, J. Vila, A. Torrents, and J. Marrugat Effect of simvastatin therapy on paraoxonase activity and related proteins in familial hypercholesterolemic patients Arterioscler. Thromb. Vasc. Biol. 20 2000 2113 2119
61. S. Deakin, I. Leviev, S. Guernier, and R.W. James Simvastatin modulates expression of the PON1 gene and increases serum paraoxonase: a role of sterol regulatory element-binding protein-2 Arterioscler. Thromb. Vasc. Biol. 23 2003 2083 2089
62. J. Beltowski, G. Wojcicka, M. Mydlarcyk, and A. Jamroz Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat Pol. J. Pharmacol. 54 2002 143 150
63. T. Hayek, S. Hamoud, S. Keidar, E. Pavlotzky, R. Coelman, M. Aviram, and M. Kaplan Omapatrilat decreased macrophage oxidative status and atherosclerosis progression in atherosclerotic apolipoprotein E-deficient mice J. Cardiovasc. Pharmacol. 43 2004 140 147
64. S. Keidar, T. Hayek, M. Kaplan, E. Pavlozky, S. Hamoud, R. Coelman, and M. Aviram Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice J. Cardiovasc. Pharmacol. 41 2003 955 963
65. B.N. La Du Is paraoxonase-3 another HDL-associated protein protective against atherosclerosis? Arterioscler. Thromb. Vasc. Biol. 21 2001 467 468
66. D.I. Draganov, P.L. Stetson, C. Watson, S. Billecke, and B.N. La Du Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation J. Biol. Chem. 275 2000 33435 33442
67. C.K. Glass, and J.L. Witztum Atherosclerosis: the road ahead Cell 104 2001 503 516
68. A.J. Lusis Atherosclerosis Nature 404 2000 231 241
69. M. Rosenblat, D.I. Draganov, C.E. Watson, C.L. Bisgaier, B.N. La Du, and M. Aviram Mouse macrophage paraoxonase 2 (PON2) activity is increased whereas cellular PON3 activity is decreased under oxidative stress Arterioscler. Thromb. Vasc. Biol. 23 2003 468 474
70. M.O. Pentikainen, K. Oorni, M. Ala-Korpela, and P.T. Kovanen Modified LDL-trigger of atherosclerosis and inflammation in the arterial intima J. Intern. Med. 247 2000 359 370
71. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity N. Engl. J. Med. 320 1989 915 924
72. M. Aviram Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases Free Radic. Res. 33 2000 S85 S97
73. D.S. Leake, and S.M. Rankin The oxidative modification of low-density lipoprotein by macrophages Biochem. J. 270 1999 741 748
74. M. Aviram, and M. Rosenblat Macrophage-mediated oxidation of extracellular low density lipoprotein requires an initial binding of the lipoprotein to its receptor J. Lipid. Res. 35 1994 385 398
75. B. Garner, D. Van Reyek, and R.T. Dean Prooxidant and antioxidant activities of macrophages in metal-mediated LDL oxidation: the importance of metal sequestration J. Biol. Chem. 272 1997 6927 6935
76. M. Aviram, and M. Rosenblat Oxidative stress in cardiovascular disease: role of oxidized lipoproteins in macrophage foam cell formation and atherosclerosis J. Fuchs M. Podda L. Packer Redox-genome interactions in health and disease 2003 Marcel Dekker Inc. New York 557 590
77. M. Aviram, and B. Fuhrman LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoproteins and in the cells: role of prooxidants vs. antioxidants Mol. Cell. Biochem. 188 1998 149 159
78. M. Rosenblat, and M. Aviram Macrophage glutathione content and glutathione peroxidase activity are inversely related to cell-mediated oxidation of LDL: in vitro and in vivo studies Free Radic. Biol. Med. 24 1998 365 371
79. M. Rosenblat, R. Coelman, and M. Aviram Increased macrophage glutathione content reduces cell-mediated oxidation of LDL and atherosclerosis in apolipoprotein E deficient mice Atherosclerosis 163 2002 17 28
80. G.M. Chisolm, S.L. Hazen, P.L. Fox, and M.K. Cathcart The oxidation of lipoproteins by monocyte-macrophages: biochemical and biological mechanisms J. Biol. Chem. 274 1999 25959 25962
81. D. Schultz, and D.G. Harrison Seeking the source of pathogenic oxygen radicals in atherosclerosis Arterioscler. Thromb. Vasc. Biol. 20 2000 1412 1413
82. B.M. Babior NADPH oxidase: an update Blood 93 1999 1464 1476
83. M. Aviram, M. Rosenblat, A. Etzioni, and R. Levy Activation of NADPH oxidase is required for macrophage-mediated oxidation of low density lipoprotein Metabolism 45 1996 1064 1078
84. I. Maor, M. Kaplan, T. Hayek, J. Vaya, A. Hoffman, and M. Aviram Oxidized monocyte-derived macrophages in aortic atherosclerotic lesion from apolipoprotein E-deficient mice and from human carotid artery contain lipid peroxides and oxysterols Biochem. Biophys. Res. Commun. 269 2000 775 780
85. B. Fuhrman, I. Oikinine, and M. Aviram Iron induced lipid peroxidation in cultured macrophages increases their ability to oxidatively modify LDL, and affect their secretory properties Atherosclerosis 111 1994 65 75
86. M. Rosenblat, and M. Aviram Oxysterols-induced activation of macrophage NADPH oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: inhibitory role for vitamin E Atherosclerosis 100 2002 69 80
87. O. Rozenberg, M. Rosenblat, R. Coleman, D.M. Shih, and M. Aviram Paraoxonase (PON1)-deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice Free Radic. Biol. Med. 34 2003 774 784
88. M. Aviram, E. Hardak, J. Vaya, S. Mahmood, S. Milo, A. Hoffman, S. Billecke, D.I. Draganov, and M. Rosenblat Human serum paraoxonases (PON 1), Q and R selectively decrease lipid peroxides in coronary and carotid atherosclerotic lesions: PON 1 esterase and peroxidase-like activities Circulation 101 2000 2510 2517
89. B. Fuhrman, N. Volkova, and M. Aviram Oxidative stress increases the expression of the CD36 scavenger receptor and the cellular uptake of oxidized low-density lipoprotein in macrophages from atherosclerotic mice: protective role of antioxidants and paraoxonase Atherosclerosis 161 2002 307 316
90. B. Fuhrman, J. Oikinine, S. Keidar, L. Ben-Yaish, M. Kaplan, and M. Aviram Increased uptake of LDL by oxidized macrophages is the result of an initial enhanced LDL receptor activity and of further progression oxidation of LDL Free Radic. Biol. Med. 23 1997 34 46
91. O. Rozenberg, D.M. Shih, and M. Aviram Human serum paraoxonase (PON1) decreases macrophage cholesterol biosynthesis: a possible role for its phospholipase-A2 activity and lysophosphatidylcholine formation Arterioscler. Thromb. Vasc. Biol. 23 2003 461 467
92. R. Sato, J.L. Goldstein, and M.S. Brown Replacement of serine-871 of hamster 3-hydroxy-3-methylglutaryl-CoA-reductase prevents phosphorylation by AMP-activated kinase and blocks inhibition of sterol synthesis induced by ATP depletion Proc. Natl. Acad. Sci. USA 90 1993 9261 9265
93. K.K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc. Res. 47 2000 648 657
94. S. Keidar, J. Attias, R. Heinrich, R. Coelman, and M. Aviram Angiotensin-II atherogenicity in apolipoprotein E-deficient mice is associated with increased cellular cholesterol biosynthesis Atherosclerosis 146 1999 249 257
95. T.S. Mikkola, M.S. Anthony, T.B. Clarkson, and R.W. St. Clair Serum cholesterol efflux potential is an independent predictor of coronary artery atherosclerosis Atherosclerosis 170 2003 31 38
96. D. Sviridov, and P. Nestel Dynamics of reverse cholesterol transport: protection against atherosclerosis Atherosclerosis 161 2002 245 254
97. A.R. Tall, P. Costet, and N. Wang Regulation and mechanisms of macrophage cholesterol efflux J. Clin. Invest. 110 2002 899 904
98. P.G. Yancey, A.E. Bortnick, G. Kellner-Weibel, M. de la Llera-Moya, M.C. Phillips, and G.H. Rothblat Importance of different pathways of cellular cholesterol efflux Arterioscler. Thromb. Vasc. Biol. 23 2003 712 719
99. B. Jian, M. de la Llera-Moya, Y. Ji, N. Wang, M.C. Phillip, J.B. Swaney, A.R. Tall, and G.H. Rothblat Scavenger receptor class B type 1 as a mediator of cellular cholesterol efflux to lipoproteins and phospholipids acceptor J. Biol. Chem. 273 1998 5599 5606
100. O.L. Francone SR-BI, a new player in an old game Arterioscler. Thromb. Vasc. Biol. 23 2003 1486 1487
101. J.F. Oram HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol Arterioscler. Thromb. Vasc. Biol. 23 2003 720 727
102. N. Wang, and A.R. Tall Regulation and mechanism of ATP-binding cassette transporter A1-mediated cellular cholesterol efflux Arterioscler. Thromb. Vasc. Biol. 23 2003 1178 1184
103. B.J. Van Lenten, A.C. Wagner, M. Navab, and A.M. Fogelman Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6 J. Biol. Chem. 273 2001 1923 1929
104. B. Fuhrman, M. Shiner, N. Volkova, and M. Aviram Cell-induced copper ion-mediated LDL oxidation increases during in vivo monocyte-to-macrophage differentiation Free Radic. Biol. Med. 37 2004 259 271